CA2163716A1 - Verotoxin pharmaceutical compositions and medical treatments therewith - Google Patents

Verotoxin pharmaceutical compositions and medical treatments therewith

Info

Publication number
CA2163716A1
CA2163716A1 CA002163716A CA2163716A CA2163716A1 CA 2163716 A1 CA2163716 A1 CA 2163716A1 CA 002163716 A CA002163716 A CA 002163716A CA 2163716 A CA2163716 A CA 2163716A CA 2163716 A1 CA2163716 A1 CA 2163716A1
Authority
CA
Canada
Prior art keywords
verotoxin
pharmaceutical compositions
medical treatments
cancer
verotoxins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002163716A
Other languages
French (fr)
Other versions
CA2163716C (en
Inventor
Clifford A. Lingwood
Hannah Farkas-Himsley
Robert Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002163716A priority Critical patent/CA2163716C/en
Publication of CA2163716A1 publication Critical patent/CA2163716A1/en
Application granted granted Critical
Publication of CA2163716C publication Critical patent/CA2163716C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1 and their pentameric subunit B, have been found to be useful in the treatment of mammalian neoplasia, particularly, brain cancer, ovarian cancer, breast cancer and skin cancer. Although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti- neoplastic in vivo. Use of a sensitizer, such as sodium butyrate, enhances the efficacy of verotoxins and their subunit B.
CA002163716A 1995-11-24 1995-11-24 Verotoxin pharmaceutical compositions and medical treatments therewith Expired - Fee Related CA2163716C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002163716A CA2163716C (en) 1995-11-24 1995-11-24 Verotoxin pharmaceutical compositions and medical treatments therewith

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002163716A CA2163716C (en) 1995-11-24 1995-11-24 Verotoxin pharmaceutical compositions and medical treatments therewith

Publications (2)

Publication Number Publication Date
CA2163716A1 true CA2163716A1 (en) 1997-05-25
CA2163716C CA2163716C (en) 2009-05-19

Family

ID=4157034

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002163716A Expired - Fee Related CA2163716C (en) 1995-11-24 1995-11-24 Verotoxin pharmaceutical compositions and medical treatments therewith

Country Status (1)

Country Link
CA (1) CA2163716C (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051326A1 (en) * 1997-05-16 1998-11-19 Hsc Research And Development Limited Partnership Inhibition of angiogenesis by verotoxins
WO1999038530A1 (en) * 1998-01-28 1999-08-05 University Of Bristol Agent capable of modulating a glycosphingolipid-associated activity thus affecting an immune disorder
WO2000029556A2 (en) * 1998-11-17 2000-05-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of glycosphingolipids that promote hiv-1 entry into cells
US7846435B1 (en) 1998-05-20 2010-12-07 Teijin Limited Humanized antibodies that recognize Verotoxin II and cell line producing same

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051326A1 (en) * 1997-05-16 1998-11-19 Hsc Research And Development Limited Partnership Inhibition of angiogenesis by verotoxins
WO1999038530A1 (en) * 1998-01-28 1999-08-05 University Of Bristol Agent capable of modulating a glycosphingolipid-associated activity thus affecting an immune disorder
US7846435B1 (en) 1998-05-20 2010-12-07 Teijin Limited Humanized antibodies that recognize Verotoxin II and cell line producing same
WO2000029556A2 (en) * 1998-11-17 2000-05-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of glycosphingolipids that promote hiv-1 entry into cells
WO2000029556A3 (en) * 1998-11-17 2000-11-23 Us Health Identification of glycosphingolipids that promote hiv-1 entry into cells

Also Published As

Publication number Publication date
CA2163716C (en) 2009-05-19

Similar Documents

Publication Publication Date Title
CA2122612A1 (en) Pharmaceutical products for curing tumourous diseases and process for preparing same
AU8469498A (en) Peptide derivatives or pharmaceutically acceptable salts thereof, method for producing the same, use of said derivatives and pharmaceutical composition
PT703786E (en) USE OF NONAPEPTIDEES AND DECAPEPTIDEOS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF AIDS
HUT71835A (en) Itraconazole and saperconazole stereoisomers, their cyclodextrin complexes and pharmaceutical compositions containing them and process for producing them
MX9302038A (en) METHOD FOR THE TREATMENT OF CANCER BY A JOINT THERAPY WITH 2-HALOMETILIDENO DERIVATIVES AND A SPECIFIC PHASE M OR PHASE S ANTINEOPLASIC AGENT.
HRP20080598T3 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
CA2373794A1 (en) Compositions and uses of et743 for treating cancer
MY107088A (en) Plaster used as therapeutic system for the administration of active substances to the skin, which exhibits a graduated active substance release,process for the production of the plaster and use thereof
RU95103892A (en) COMPOSITION FOR TOPIC APPLICATION FOR HAIR GROWTH STIMULATION AND/OR THEIR FALLING OUT RETARDATION, METHOD OF COSMETIC HAIR TREATMENT, USE OF α-PYRONE DERIVATIVE FOR COMPOSITION PREPARING
BR9608731A (en) Use of 1,2,4-triazole derivatives to produce a cancer treatment drug
WO2000072823A8 (en) Preparations for the application of anti-inflammatory agents
GEP20043202B (en) Resorcinol Derivatives
CA2163716A1 (en) Verotoxin pharmaceutical compositions and medical treatments therewith
WO2000008007A3 (en) Cyclopentabenzofuran derivatives and their use
CA2116179A1 (en) Verotoxin pharmaceutical compositions and medical treatments therewith
AU5691796A (en) Terpenoidic derivatives useful as antitumor agents
MX9203405A (en) ACTIVE COMPOUNDS TO BE USED IN THE TREATMENT OF TUMORS.
TR200401810T4 (en) Use of fsh for infertility treatment
GB9505082D0 (en) Medicament
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
IL135171A0 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
IT8448710A1 (en) REDUCTION OF TOXIC EFFECTS CAUSED BY ANTHRACHINONIC DRUGS
KR950023398A (en) Beauty bamboo salt
RU94003538A (en) A METHOD OF INCREASING THE EFFICIENCY OF RADIOTHERAPY THERAPY
IT1265649B1 (en) Dermatological product for topical use, corresponding production process and therapeutic use in skin burns and diseases

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151124